One of the first requirements for a successful gene-based treatment approach for the cornea is to identify the genes that need to be augmented, replaced, or edited, or identification of the pathways to be targeted by the protein product of the selected transgene.
TGFβI-associated dystrophies have been attributed to various mutants in
TGFβI gene, with positions 124 and 555 being the most common. Deposition of TGFβ-induced (TGFβ) protein aggregates in the stroma or Bowman layer have been associated with these dystrophies
[22]. Several uncommon mutations are scattered across five of the gene’s 17 exons and are associated with divergent clinical presentations of the dystrophy, including Reis–Bucklers corneal dystrophy, Thiel–Behnke corneal dystrophy, lattice corneal dystrophy type 1, granular corneal dystrophy type 1, and granular corneal dystrophy type 2. Epithelial recurrent erosion dystrophy (ERED) is caused by mutation in the
COL17A1 gene
[23]. Until the discovery of this mutation, Thiel–Behnke corneal dystrophy was thought to result only from mutations in the
TGFBI gene. Heterozygous mutations in the
KRT3 or
KRT12 genes, encoding corneal specific Keratins 3 and 12, respectively
[24], have been associated with Meesmann epithelial corneal dystrophy (MECD), a rare autosomal dominant inherited disease. Malfunction of K3 and K12 has been shown to cause mechanical fragility of the anterior corneal epithelium
[25]. Various studies have identified at least 24 mutations for MECD, most of which are missense point mutation
[24][26][27][28]. Early onset Fuchs endothelial corneal dystrophy (FECD) has been associated with mutations in the
COL8A2,
SLC4A11,
ZEB1, and
LOXHD1 genes. The majority of FECD cases are caused by a trinucleotide repeat expansion in the
TCF4 gene
[29], leading to altered mRNA processing due to sequestration of splicing factor proteins (MBNL1 and MBNL2) to the nuclear RNA foci.
Corneal neovascularization occurs in various corneal pathologies, including inflammatory diseases, congenital diseases, contact lens-related hypoxia, inflammatory diseases, autoimmune diseases, chemical burns, trauma, corneal graft rejection, and infectious keratitis
[40], which may lead to significant visual impairment or blindness
[41]. Various angiogenic factors, such as VEGF, basic fibroblast growth factor (bFGF), matrix metalloproteinase (MMP), platelet-derived growth factors (PDGFs), and interleukin-1 (IL-1), mediate corneal neovascularization. In the retina and the cornea, VEGF-A is the predominant VEGF member driving pathologic neovascularization and is therefore a potential target of several drugs. The VEGF-A binds to two members of receptor tyrosine kinase family, VEGF receptors VEGFR1 and VEGFR2, also known as Flt-1 and KDR, respectively. Vascular endothelial cells (VECs) significantly express both of these receptors, and their expression increases in the presence of inflammation. It has been found that their activation promotes vascular leakage, VEC liberation, and VEC proteolysis
[42][43]. Targeting these factors and inhibiting their expression or increasing expression of anti-angiogenic factors may help inhibit angiogenesis. Bevacizumab and ranibizumab are currently used in clinical settings to inhibit VEGF-A signaling pathways
[44]. When mixed with non-liposomal lipid and delivered by means of subconjunctival injection, the brain-specific angiogenesis inhibitor 1 (
BAI1-ECR) gene showed an effective reduction of corneal neovascularization
[45]. Several of these targets that mediate neovascularization, including
Flt23k,
Flt-1,
PEDF,
VEGFR Flt-1,
MMP-9, and
vasohibin-1 [46][47][48][49][50][51], could serve as a potential target candidates for corneal gene therapy.
3. Gene Therapy for Corneal Diseases
Gene therapy is a technique in which replacing or inactivating (knocking out) the mutated gene occurs as a result of targeted therapeutic delivery of correct nucleic acid directly into the patient’s cells. Gene therapy to treat any inherited corneal dystrophies works via three approaches: (a) Gene inactivation or silencing of the mutated gene that manifests a toxic effect on the cells; (b) Gene correction or replacement of the mutated gene with a normal copy of a healthy gene; and (c) Addition of a healthy copy of the gene that will ectopically express the therapeutic protein to rescue the disease phenotype. Gene therapy has a growing potential in the field of corneal dystrophies due to three major characteristics: accessibility in terms of injections and surgical interventions; its partial immune-privileged properties that limit immune responses towards the antigenicity of the transgene and the viral vectors; and the presence of a tight blood-retinal barrier that can help to prevent unintentional spreading or contamination of the neighboring tissues as well as to the general circulation. In addition, direct corneal delivery, either topically or via injection, can be achieved only in the affected eye in the case of unilateral conditions. The advancement in imaging technologies, such as pentacam and adaptive optics, further facilitates quantitative and qualitative evaluation of corneal changes after gene therapy. However, the wide heterogeneity in disease-causing genes in hereditary corneal disease requires knowledge and identification of the specific causative gene in each patient in order to consider gene therapy as an intervention. However, many of the pathways affected in the tissues as part of their pathology can be common. Therefore, there is a need to design differential strategies according to the causative genes, mutation, and inheritance pattern for gene therapy of various hereditary corneal dystrophies. The success of gene therapy for the treatment of any disease depends on the efficiency by which the therapeutic transgene is delivered to the target cell type. There are currently two main approaches in terms of vectors for delivering genetic material: viral and non-viral vectors.
3.1. Viral Vectors
Significant progress in understanding the molecular mechanism of diverse corneal diseases has led to the development of gene therapies in animal models. Gene therapy in animal models has demonstrated restoration of the biomechanical stability of the cornea by regulating the key proteins that are deficient in various corneal dystrophies, thus establishing a scientific basis for application in human subjects. Most studies on gene therapy of diverse corneal dystrophies have used viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus, due to their unique ability to transduce a wide tropism of living cells with minimal resistance. The mechanisms by which the viral vectors deliver the therapeutic gene and translate the therapeutic protein into the host cells is discussed in this section.
3.1.1. Adeno-Associated Virus (AAV)
AAV is a small (25-nm), non-pathogenic, nonenveloped virus that packages a linear single-stranded DNA genome of ~4.7 kb containing two genes that produce 4 Rep and 3 Cap proteins for replication and capsid proteins, respectively (
Figure 2). The Rep gene encodes for four different proteins: rep40, rep52, rep68, and rep78. Rep68 and rep78 play an essential role in viral genome integration, replication, and transcriptional regulation of AAV gene expression, whereas rep 40 and rep 52 proteins are involved in viral genome encapsulation. The cap gene encodes three viral capsid proteins, VP1 (90 kDa), VP2 (72 kDa), and VP3 (60 kDa) (
Figure 2), which are arranged in a 1:1:10 ratio and form an icosahedral symmetry. AAV belongs to the family Parvoviridae and is placed in the genus Dependovirus
[80], as AAV requires a helper virus, such as adenovirus, to establish a productive infection cycle. However, recombinant AAV vectors used for gene therapy do not carry any of its native Rep/Cap genes or any helper genes, underlining its safety profile for therapeutic applications. Additionally, these vectors can transduce and express in both mitotic and post-mitotic cells.
Figure 2. Schematic illustration of (A) AAV genome, and (B) mechanism of entry, infection, and therapeutic gene production in host cell.
The ability of the various rAAV serotypes to transduce a wide variety of ocular structures is due to its ability to bind primary cell surface receptors such as heparin sulphate proteoglycan (HSPGs)
[81]. HSPGs are expressed in most of the cell types and uses integrin αvβ5 or fibroblast growth factor receptor (FGFR) as coreceptors for its internalization and endocytosis
[82][83]. Once endocytosed, the viral particles are released from the endosome at a low pH
[84][85]. The released SS-DNA of AAV is converted to ds-DNA by either annealing to another complementary strand of AAV or via the host cell DNA replication machinery. Subsequently, the viral genome remains as an episome and, with the help of host cell machinery, undergoes transcription and translation to produce the deficient therapeutic protein in the target cells over extended durations (
Figure 2).
The ability of the various rAAV serotypes to transduce ocular structures at the anterior segment of the eye has been extensively documented using vectors encoding marker proteins; therefore, it has become evident that a combination of serotypes, route of administration, and the choice of regulatory elements such as promotors allows the selective tropism of desired cell types. Recent studies have also shown that the corneal stroma is an ideal target for AAV-mediated gene therapy where the quiescent stromal keratocytes can receive the vectors and express the therapeutic proteins over long durations. In the context of corneal gene therapy, the first reported gene therapy was mediated by the AAV2 serotype, which demonstrated successful transgene delivery into a rabbit cornea in vivo
[86]. The natural occurrence of the AAV2 serotypes may cause its pre-exposure in humans. This exposure leads to the production of neutralizing antibodies against the serotype. Thus, when a therapeutic gene packaged into a AAV2 serotype is delivered to the patient there is a chance of eliciting a humoral immune response against it which in turn may diminish the efficacy and safety of viruses carrying the therapeutic gene. The AAV5 serotype has been found to be the most divergent serotype
[87], with a several-fold more efficient transduction efficiency than AAV2
[88]. In vivo gene therapy for corneal scarring using topical administration of the AAV5 serotype in rabbit models has shown a significant decrease in corneal haze and fibrosis, without any reports of any immunogenic or toxic immune response against it
[89][90]. In the domain of AAV vectors, AAV8
[91] and AAV9
[92] were considered the most efficient in corneal keratocyte transduction. Therefore, a chimeric AAV capsid was generated where an AAV8 capsid scaffold was engrafted with the AAV9 galactose binding domain. On evaluating the potency of infection of the chimeric AAV8/9 capsid following an intrastromal injection of the vectors into the human donor eyeballs, efficient widespread transduction of the transgene was observed. The AAV8/9 chimeric capsids were found to have greater and more efficient transduction efficiency when compared to either parent serotype at similar vector doses
[93]. Therefore, a direct gene augmentation strategy using AAV vectors offers a viable option to cure diseases for which no treatment options exist.
3.1.2. Lentivirus (LV)
Lentiviruses are single-stranded enveloped RNA viruses and are members of the retroviridae family. A mature LV is 100 nm in diameter and has a cylindrical core structure. LV transduction takes place through association with specific cell surface receptors. After binding to the receptor, the viral membrane fuses with the host cell membrane
[94] and injects the nucleoprotein complex into the cell. After its entry, the viral RNA is reverse-transcribed into ds-DNA by the reverse transcriptase enzyme associated with the nucleoprotein complex. The ds-DNA enters the nucleus through the nuclear pore complex and is integrated into the host genome with the help of the viral integrase
[95] (
Figure 3). The cons of using LVs as a vector for corneal gene therapy are that it possesses high immune cell infiltration post-infection, random integration potential
[96][97], and a consequent risk of insertional mutagenesis/teratoma formation. Due to these crucial shortcomings, the use of LVs still requires immense evaluation and identification of preferential integration sites in the host genome before being applicable to humans for therapies.
Figure 3. Schematic illustration representing mechanism of action of (A) adenovirus and (B) lentivirus.
3.1.3. Adenovirus (Ad)
Adenoviruses are double-stranded enveloped DNA viruses and are members of the Adenoviridae family. More than 50 known human adenoviral serotypes are present in nature, of which serotypes 2 and 5 are the most widely used in gene therapy. Ad vectors can transduce both dividing and non-dividing cells. It can harbor a therapeutic gene up to 30Kb in size and deliver it to the target tissue. Their inability to integrate into the host genome reduces the chances of insertional mutagenesis. In adenoviral vector preparations, high titers of pure viruses can be easily obtained from a single viral prep, thus a small volume of vector injection into the cornea is enough for a high level of transduction. The Ad vectors deliver the therapeutic gene in the host cell through receptor-mediated endocytosis
[98], by binding to the cell surface coxsackie adenovirus receptor, αvβ3 integrin, and clathrin-coated pits. Once internalized, the viral genome containing the therapeutic gene is released into the cytoplasm which further enters the nucleus through the nuclear pore complex and remains distinct from the host genome and is expressed as episomes to produce the therapeutic protein (
Figure 3). However, the shortcomings were the short-lived expression of the delivered transgene, primarily due to the rapid histone association and silencing of the Ad genome. This necessitates repeated vector injection, which showed more toxic responses to the cells than the original exposure
[99]. The Ad capsid structures (the pentons and heptons) are potent targets for rapid immune recognition causing Ad mediated gene therapy to typically induce significant host immune response
[100].
3.2. Non-Viral Vectors
The delivery of the therapeutic gene into the cornea can also be achieved using a non-viral origin vector mediated gene therapy. This includes the use of liposomes, compacted nanoparticles, electroporation, particle gun bombardment, and many other methods. The advantage of non-viral vectors is low immunogenicity, ease of manipulating their chemical properties to suit DNA delivery, the possibility of large-scale production, and transferring large vectors without any immune reactions. However, non-viral vectors may present obstacles such as inefficient cellular membrane transport, intracellular/extracellular degradation, and lack of long-term gene expression
[101].
3.2.1. Electroporation
Electroporation is a technique that uses short and intense electric pulses to create pores or reversibly permeabilize the cell membrane in order to deliver the naked circular DNA carrying the therapeutic gene into the target cells (
Figure 4). This physical method of non-viral mediated gene therapy has been widely used for successfully delivering plasmid DNA into the corneal endothelium and stromal keratocytes
[102][103]. The optimal field strength of 100–200 V/cm was found to be suitable for the transfer of naked plasmid DNA without any corneal damage or inflammation. Various in vivo experiments on different animal models for stromal keratitis and corneal endothelium wound healing experiments showed a 1000-fold increase in gene uptake in the cornea in comparison to injection of DNA alone, leading to inhibition of the disease phenotype
[20][104]. One of the main drawbacks when using electroporation is that the permeabilization as a result of the electric pulse becomes irreversible due to the heat generated during the process
[105].
Figure 4. Delivery mechanism for non-viral vectors.
3.2.2. Nanoparticles
Nanoparticles are ultrafine particles that range between 1 and 100 nm in size and are widely used in nanomedicine due to their (a) small size, (b) ability to deliver the transgene into the intracellular compartment of the cells, (c) high surface area to volume ratio, (d) capability to deliver a larger payload, and (e) negligible toxic damage to the cell membrane. The use of nanoparticles is highly suitable for the delivery of transgene for the treatment of eye-related diseases as they can permeabilize across various ocular barriers including the cornea, sclera, conjunctiva, and, in some cases, the blood-retinal barriers. Nanoparticles can harbor multiple cargo types, including DNA, peptides, antibodies, molecular sensors, and drugs, in the desired cellular layers of the eye. Nanoparticles are mainly classified as metallic, polymeric, and hybrid nanoparticles. Polymeric nanoparticles that are usually prepared from albumin, chitosan, and polyethyleneimine (PEI) have been found to be more efficient in delivering the transgene into rodent corneas in vivo without any significant side effects
[106][107][108]. In vivo delivery of transgene using hybrid nanoparticles in rabbit cornea to treat corneal fibrosis has demonstrated an efficient cargo of transgene in the target cells with significant inhibition of fibrosis and no visible toxic effects
[36].
The direct transfer of the therapeutic gene to the corneal cells in vivo has been achieved using cationic lipids
[109]. The positively charged cationic lipids bind to negatively charged DNA molecules to form a lipid-DNA complex that has a high affinity for the cell membrane. The lipid-DNA complex is then endocytosed into an endocytic vesicle followed by its trafficking and release from the endosomal compartment. The nuclear uptake of the DNA takes place through the nuclear pore complex, which then forms an episome to express the therapeutic protein using the host cell machinery
[110] (
Figure 4).
3.3. Gene Therapy Strategies for Precise and Targeted Therapeutics
3.3.1. Gene Augmentation
Gene augmentation therapy is a straightforward approach in which the transfer of the functional therapeutic gene into the affected cells takes place to restore the expression of an inadequately functioning gene
[111][112] (
Figure 5). This approach is mainly applicable to recessive genetic diseases. For the augmentation strategy to be effective, the augmented transgene must synthesize physiological and adequate levels of the normal protein and the tissue status and disease stage at which treatment is attempted should not be terminal. To minimize off-target transgene expression that may have a pathogenic effect within the cells, it is important to focus on the appropriate regulation of the transgene expression for augmentation-based approaches. To address appropriate transgene regulation, cell or tissue-specific promoter sequences can be designed to modulate the expression of the therapeutic transgene. For example, in response to inflammation, NFκB responsive promoter sequences have been used to drive the transgene expression in immune organs
[113]. A commonly used approach in gene augmentation therapy for secretory protein is to target the delivery of the therapeutic gene to a distant tissue/cell and not the affected cell type or tissue; this will help in the production of the same deficient therapeutic secretory protein to rescue the disease phenotype. This approach can be adopted when (i) transduction of affected cells with the therapeutic gene may not be able to produce a physiologically relevant amount of secreted transgene protein; (ii) the affected site of gene delivery has been rendered sensitive to any further damage that can be caused during the gene delivery procedure; and (iii) the site of gene delivery is highly exposed to the host immune system which can lead to a transgene-directed immune response. Such an approach in corneal gene therapy has not yet been listed in the literature.
Figure 5. Schematic illustration for the different strategies used in corneal gene therapy. (A) Gene augmentation. (B) Gene silencing using ASO, siRNA, and miRNA. (C) Gene editing using CRISPR Cas9 approach.
Gene augmentation therapy for corneal diseases has been conducted in various animal models in vivo to rescue the disease phenotype. There are numerous studies that have shown that gene augmentation using viral and non-viral vectors can help to significantly improve the disease pathology in murine, ovine, and canine models.
3.3.2. Gene Editing
In recent times, gene editing has become one of the most utilized approaches in the field of gene therapy. This approach is able to target both autosomal dominant and recessively inherited corneal dystrophies that lead to loss of function due to mutation of the target gene. The strategy aims to restore/correct the normal functioning of the mutated gene by adding, removing, or altering the genome at the site of the mutation. One of the most specific and advanced genome editing technologies to date that has been used for gene correction in the anterior segment of the eye is Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated (Cas) proteins, termed the CRISPR-Cas system
[114]. Meganucleases, Zinc finger nucleases (ZFNs)
[115], and transcription activator-like effector nucleases (TALENs) are also used in this approach. CRISPR-Cas-based genome editing has been found to be more favorable than the other mentioned nucleases due to its relatively simple design for targeting the mutated gene
[116]. On the other hand, significant modifications in the DNA-binding protein domains are required to target with ZFNs and TALENs.
The mechanism of CRISPR-Cas 9 involves the binding of Cas9 nuclease at the genomic locus that is complementary to the guide RNA; this guide RNA creates a double-stranded break, which is repaired via two mechanisms: (i) error-prone non-homologous end joining (NHEJ) or (ii) homologous directed repair (HDR) (
Figure 5). NHEJ can create insertions or deletions in the mutated gene, resulting in the formation of a premature stop codon. This can be used to knock out the expression of the truncated protein. HDR can help incorporate specific alterations into the mutated gene provided by the repair template. All studied Cas9 enzymes require a protospacer adjacent motif (PAM) next to the target site for target DNA recognition. Some recent studies have also shown the ability of certain divergent CRISPR-Cas9 enzymes that can recognize and cleave single-stranded DNA (ssDNA) using an RNA-guided, PAM-independent recognition mechanism
[117]. Intravenous delivery of the CRISPR-Cas9 system cannot be used in the eye due to the blood-ocular barrier
[118]. AAV as a vector has been widely used for the delivery of CRISPR-Cas9 construct into the target tissue/cell. However, the biggest shortcoming of using AAV vectors is their carrying capacity. They are often too small to accommodate the full genome editing system. To address this issue, a dual-AAV vector design has been implemented in which the Cas9 nuclease and the single-guide RNA (sgRNA) cassettes have been packaged in two separate vectors and delivered to the target tissue, which showed highly efficient genome editing in the hepatocyte cells
[119]. The CRISPR-Cas 9 system has been used to treat corneal dystrophy in animal models. In one study, selective disruption of the mutated copy of the
KRT12 gene in a humanized MECD mouse model was achieved by targeting the protospacer adjacent motif (PAM) sequence that was generated by the missense mutation in the
KRT12 gene
[120].
3.3.3. Gene Silencing
Gene augmentation therapy is likely to be ineffective in rescuing the disease phenotype in autosomal dominant diseases. For augmentation therapy to work effectively, the suppression of the mutated gene expression must be addressed first. Silencing the mutated gene can be mediated via delivering a small double-stranded non-coding RNA construct that is designed to act via RNA interference (RNAi)
[121]. RNAi promotes post-transcriptional gene silencing by enzymatic degradation of the complementary RNA species. This silencing is mediated by a large multi-component RNA/protein complex called the RNA-induced silencing complex (RISC)
[122] (
Figure 5). siRNAs (small interfering RNA) have been tested in various corneal dystrophies, including MECD, wound healing, and neovascularization
[123][124][125].
In the context of mRNA-based gene therapy, the most successful approach is the use of antisense oligonucleotides (AONs). AONs are short single-stranded DNA or RNA that interacts with the complementary mRNA to block the translation by altering the pre-mRNA splicing
[126]. The first AON approved by the FDA was for the treatment of cytomegalovirus retinitis: fomivirsen (Vitravene). In the cornea, the first phase clinical trial was conducted to explore the efficacy of a topically administered AON (Aganirsen) that targets the insulin substrate-1 receptor to block corneal neovascularization in keratitis patients. The AON administration was found effective and thus reduced the need for corneal transplantation
[127]. GS-101 AON was also found to be a potent anti-angiogenic compound that helped in the significant regression of corneal neovascularization
[128].
Despite gaining success, the strategy of gene silencing fails to completely silence the target gene expression. For the RNAi pathway, the major drawbacks, such as off-the-mark effects and extended toxicity of the small RNA molecules, must be considered and studied carefully for its successful application in clinical settings.
3.3.4. Dual Vectors
Limitations of using rAAV-based gene therapy correctional strategies include its limited packaging size for genes larger than 4.7 kb such as PD-L1, which is widely used in corneal graft rejection studies. Several strategies have been designed to take advantage of the head-tail concatamerization of the AAV genome (
Figure 6). One strategy is to use the overlapping sequence approach. In this method, efficient reconstitution and transgene expression rely on the use of two separate (dual) AAV vectors, each one carrying half of a large gene. Upon coinfection of the target cell from both vectors, the two halves will be reconstituted due to the canonical ability of AAV genomes to concatamerize via intermolecular recombination. In 2007, Ghosh et al.
[129] developed a hybrid dual vector strategy to expand the packaging capacity in the rAAV system, the trans-splicing vectors, and showed effective, whole-body transduction using a mouse model of Duchenne Muscular Dystrophy. This trans-splicing strategy employs the use of a splice donor at the 3′ end of one-half of the target gene in one vector and a splice acceptor at the 5′ end of the other half of the transgene. This allows for efficient reconstitution of the mRNA transcripts by the head-to-tail concatamerization process. The third dual AAV approach (hybrid) is a combination of the two previous approaches; it is based on the addition of a highly recombinogenic exogenous sequence (recombinogenic region) to the trans-splicing vectors in order to increase their recombination efficiency. In 2011, Ghosh et al.
[130] reported the use of minimized bridging sequences from the highly recombinogenic alkaline phosphatase (~227–247 bp) to circumvent the available space for packaging the transgene. In this approach, the authors demonstrated the complete reconstitution of the B-Galactosidase gene (LacZ) when packaged separately and co-infected to check expression. Expression of the reconstituted LacZ was proven to be better than the original hybrid strategy developed in suitable cell cultures and animal models.
Figure 6. Schematic illustration representing dual AAV approach for large genes.